IP
IndiaPulse

IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Small Cap

Industrials stocks · Small cap · NSE

IOL Chemicals and Pharmaceuticals Limited operates in API, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹199.95
+3.52 · +1.79%
Quote04 Sept, 03:59 pm IST
Fundamentals05 Sept 2026 · screener
Score05 Sept, 10:20 pm IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.4 (n=540)
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.

Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
U-Score
WATCHLIST
36

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Healthy Trust
80

low confidence · 0/0 claims checked

Technical
Bullish
66

Timing lens: price trend and sector relative strength.

Result consistency
stable
79

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 30 Jun 2026

Excellent · 100/100

Rev +37% YoY · PAT +88% YoY · margin expansion · +22% QoQ · operating leverage

Filed 30 Jun 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹756 Cr+37.0%+22.1%
EBITDA₹103 Cr+66.1%+12.0%
Operating margin14.0%+300 bps-100 bps
PAT₹64 Cr+88.2%+20.8%
PAT margin8.5%+231 bps-9 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business & thesis

Growth engines, tailwinds/headwinds, and risk radar from management commentary

Business and thesis

Issuer presentation review pending

IOL Chemicals and Pharmaceuticals Limited operates in API, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Management accountability

What management said, and what results must prove

Technical timing lens

Trend score and candlestick chart

66Bullish

full bull SMA stack · SMA20 +13.0% / mo · RSI overbought · MACD + · near 52W high

Stock trend: 78
Sector RS: 48
Sector 3M: -1.6% vs Nifty -1.5%

Technical chart

IOLCPdaily · 1Y · AUTO+182.1%
Latest close ₹199.95 on 2026-09-04
Bar
+1.5%
RSI
73
MACD hist
2.09
52W pos
96%
2026-09-04O ₹197.00H ₹204.98L ₹192.50C ₹199.95Vol 52.9L sh
₹60.30₹98.19₹136.08₹173.98₹211.8752H52L199.952026-032026-06VolRSIMACD2026-032026-042026-062026-072026-09
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal

Daily technical trend read

Mixed signals

Signals are conflicting — long-term uptrend intact. RSI 73. Wait for confirmation.

  • Price > SMA20 > SMA50 > SMA200 — full bullish stack.
  • SMA20 rising (~11.5% over last month) — short-term momentum positive.
  • RSI(14) at 73 — overbought zone; risk of mean reversion.
  • MACD above signal but histogram contracting — bullish momentum cooling.
  • Within 3% of 52-week high — testing resistance.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Valuation & score drivers

U-Score 36 · WATCHLIST · pillar breakdown, sector model, fair-value anchor

36U-SCORE
WATCHLIST

Fundamental score breakdown

WATCHLIST
Valuation4/30
Growth10/25
Quality2/20
Balance Sheet12/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
36

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

36/100 · WATCHLIST

Positive drivers

  • Piotroski is strong at 8/9.
  • Fair-value margin of safety is positive at 22.3%.
  • Balance sheet contributes 12/15 to the score.

Main drags

  • Penalty bucket subtracts 1 points.
  • Quality is weaker at 2/20; verify the latest quarterly trend.
  • Valuation is weaker at 4/30; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
33.3
PB
3.3
EV/EBITDA
15.3
ROE
8.4%
ROCE
11.3%
FCF Yield
0.3%
Debt/Equity
0.1
MoS
+22.3%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 05 Sept 2026
v4.3-runtime-valuation
Final score
36
Previous: 36
Verdict
WATCHLIST
Previous: WATCHLIST
Margin of safety
+22.3%
Previous: +22.3%

Score history

12 stored score snapshots. Latest stored move: +6 points.

05 Sept 2026
v4.3-runtime-valuation
32
32
28
28
28
29
29
30
28
30
30
36

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
₹88.82
-125.1% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹257.4
+22.3% MoS
PEG
4.16

Trust score

Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth

Trust Score
80Healthy Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Healthy Trust: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 89th percentile within Industrials. No major sub-score weakness stands out.

High Trust Lite: Promoter holding is 62.3%.

Computed 05 Sept 2026
management-trust-v1
99 docs text-extracted · 46 concalls text-extracted
Score band
Healthy Trust

Generally investable credibility. Look for weak sub-scores before increasing position size.

Relative rank
90th percentile

overall median 67 · Industrials: 89th pctile, median 68 · Small: 92nd pctile, median 66

Evidence depth
Financial-only

99 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Healthy Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
90
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
79
strong · quarterly consistency

Trust positives

  • Promoter holding is 62.3%.
  • Promoter pledge is zero.
  • Promoter holding increased 9.7%.
  • FCF yield is positive at 0.3%.

Trust risks

  • No major Trust Lite risk flags.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Financials

Full fundamentals table and 10-year revenue / profit / ROE history

Fundamentals

Valuation

P/E
33.30
P/B
3.26
EV/EBITDA
15.32
Market Cap
5869.00Cr

Profitability

ROE
8.41%
ROCE
11.30%
ROA
6.49%
Dividend Y
0.50%

Growth (CAGR)

Revenue 5Y
12.00%
EPS 5Y
12.00%
Revenue 3Y
2.00%
EPS 3Y
2.00%

Balance Sheet

Debt/Equity
0.08
Interest Coverage
22.14×
Altman Z
7.03
Book Value
61.30

Cash Flow

FCF Yield
0.27%
FCF Positive Y
4/5
OCF
214.00 Cr
EPS TTM
5.72

Shareholding

Promoter Hold
62.28%
Promoter Pledge
0.00%
Momentum 52W
96%

Financial History

Updated 5/9/2026

Revenue

₹ Cr
No data

Net Profit

₹ Cr
No data

Return on Equity

%
No data

Peers

Business-comparable names in Industrials, ranked by similarity

Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.